Abstract
The HIV-1 Vpr protein is a viral accessory protein that plays a number of important roles during HIV infection. The activities of Vpr are numerous and include the induction of apoptosis, the modulation of cell cycle arrest, as well as control of viral transcription. Study of HIV clones lacking Vpr in vitro and analysis of HIV variants isolated from longterm nonprogressors in vivo highlight the importance of Vpr for viral replication as well as immune suppression and cell death. Vpr may therefore be considered among the most important accessory proteins encoded by HIV.
Keywords: HIV-1, viral protein R (Vpr), viral transcription, apoptosis, cell cycle arrest, mitochondrial membrane potential and immune suppression
Current HIV Research
Title: HIV-1 Vpr: Regulator of Viral Survival
Volume: 7 Issue: 2
Author(s): Khanh P. Thieu, Matthew P. Morrow, Devon J. Shedlock, Kimberly A. Schoenly, Karthikbabu Mallilankaraman, Andrew Y. Choo, Paolo Fagone, David B. Weiner and Karuppiah Muthumani
Affiliation:
Keywords: HIV-1, viral protein R (Vpr), viral transcription, apoptosis, cell cycle arrest, mitochondrial membrane potential and immune suppression
Abstract: The HIV-1 Vpr protein is a viral accessory protein that plays a number of important roles during HIV infection. The activities of Vpr are numerous and include the induction of apoptosis, the modulation of cell cycle arrest, as well as control of viral transcription. Study of HIV clones lacking Vpr in vitro and analysis of HIV variants isolated from longterm nonprogressors in vivo highlight the importance of Vpr for viral replication as well as immune suppression and cell death. Vpr may therefore be considered among the most important accessory proteins encoded by HIV.
Export Options
About this article
Cite this article as:
Thieu P. Khanh, Morrow P. Matthew, Shedlock J. Devon, Schoenly A. Kimberly, Mallilankaraman Karthikbabu, Choo Y. Andrew, Fagone Paolo, Weiner B. David and Muthumani Karuppiah, HIV-1 Vpr: Regulator of Viral Survival, Current HIV Research 2009; 7 (2) . https://dx.doi.org/10.2174/157016209787581454
DOI https://dx.doi.org/10.2174/157016209787581454 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>In Silico</i> Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry ING Proteins in Cellular Senescence
Current Drug Targets Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Clinicopathological Significance of Long Non-Coding RNA <i>GHET1</i> in Human Cancers: A Meta-Analysis
Current Pharmaceutical Biotechnology Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II A)
Current Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry HIV-1 Integrase: From Biology to Chemotherapeutics
Current HIV Research The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Research and Development of B-Raf Inhibitors
Current Medicinal Chemistry P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Design, Synthesis and Biological Activity of New Polyenolic Inhibitors of Matrix Metalloproteinases: A Focus on Chemically-Modified Curcumins
Current Medicinal Chemistry Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design